Characteristics of patients studied for WT1 MRD and comparison of patients with and those without WT1 MRD assessment after induction chemotherapy
| . | WT1 MRD available (n = 314) . | WT1 MRD missing (n = 72) . | P . |
|---|---|---|---|
| Male, n (%) | 165 (52.5) | 40 (55.6) | .695 |
| Median age, y [IQR] | 46 [36-54] | 48 [40-54.5] | .114 |
| Median WBC count, 109/L [IQR] | 9.8 [2.71-31.25] | 10.75 [3.58-49.73] | .3 |
| ALFA risk classification, n (%)* | .0436 | ||
| Favorable | 79 (26) | 27 (39.7) | |
| Intermediate | 131 (43.1) | 28 (41.2) | |
| Unfavorable | 94 (30 .9) | 13 (19.1) | |
| ELN 2017 risk classification, n (%)† | .115 | ||
| Favorable | 126 (42.4) | 37 (55.2) | |
| Intermediate | 87 (29.3) | 18 (26.9) | |
| Unfavorable | 84 (28.3) | 12 (17.9) | |
| NPM1 mutation, n (%)‡ | 130 (42.2) | 42 (60) | .0079 |
| FLT3-ITD, n (%)§ | 87 (28.2) | 20 (28.6) | .99 |
| FLT3-TKD, n (%)ǁ | 21 (6.9) | 10 (14.3) | .0531 |
| Induction cycle to reach CR, n (%) | .192 | ||
| 1 | 290 (92.4) | 70 (97.2) | |
| 2 | 24 (7.6) | 2 (2.8) | |
| Postremission randomization, n (%) | .0018 | ||
| HDAC | 62 (19.7) | 4 (5.6) | |
| CLARA | 62 (19.7) | 10 (13.9) | |
| Not randomized | 190 (60.5) | 58 (80.6) |
| . | WT1 MRD available (n = 314) . | WT1 MRD missing (n = 72) . | P . |
|---|---|---|---|
| Male, n (%) | 165 (52.5) | 40 (55.6) | .695 |
| Median age, y [IQR] | 46 [36-54] | 48 [40-54.5] | .114 |
| Median WBC count, 109/L [IQR] | 9.8 [2.71-31.25] | 10.75 [3.58-49.73] | .3 |
| ALFA risk classification, n (%)* | .0436 | ||
| Favorable | 79 (26) | 27 (39.7) | |
| Intermediate | 131 (43.1) | 28 (41.2) | |
| Unfavorable | 94 (30 .9) | 13 (19.1) | |
| ELN 2017 risk classification, n (%)† | .115 | ||
| Favorable | 126 (42.4) | 37 (55.2) | |
| Intermediate | 87 (29.3) | 18 (26.9) | |
| Unfavorable | 84 (28.3) | 12 (17.9) | |
| NPM1 mutation, n (%)‡ | 130 (42.2) | 42 (60) | .0079 |
| FLT3-ITD, n (%)§ | 87 (28.2) | 20 (28.6) | .99 |
| FLT3-TKD, n (%)ǁ | 21 (6.9) | 10 (14.3) | .0531 |
| Induction cycle to reach CR, n (%) | .192 | ||
| 1 | 290 (92.4) | 70 (97.2) | |
| 2 | 24 (7.6) | 2 (2.8) | |
| Postremission randomization, n (%) | .0018 | ||
| HDAC | 62 (19.7) | 4 (5.6) | |
| CLARA | 62 (19.7) | 10 (13.9) | |
| Not randomized | 190 (60.5) | 58 (80.6) |